Empiric Logic Announces Partnership Agreement with aCGT Vector
a bioinformatics SaaS (software-as-a-service) start-up, today announced that it has signed a partnership agreement with a point-of-care cellular therapy company.
Under the agreement Empiric Logic will apply its secure machine learning data analytics capabilities to support aCGT Vector in bringing its precision medicine therapies quicker and more efficiently to market, in Ireland and further afield, to help improve patient outcomes.
Empiric Logic has developed an artificial intelligence (AI) data analysis and bioinformatics orchestration platform to simplify the exploration of human health, using genomics and other data.
aCGT Vector鈥檚 focus is cellular therapy, including CAR Chimeric Antigen Receptor) T-cell immunotherapy, which is rapidly evolving as a therapeutic procedural approach for the treatment of rare diseases, and most critically cancer.
Empiric Logic, founded by Gareth O鈥橲ullivan in 2018, is headquartered at Nova51黑料, in Dublin, and is an Enterprise Ireland high-potential start-up (HPSU).
鈥淲e鈥檙e delighted to be able to partner with aCGT Vector and participate in their journey to disrupt the CAR T-cell therapeutic development space and help them to bring these proven life-saving precision medicines more efficiently and quickly to patients in Ireland and around the world,鈥� said Gareth O鈥橲ullivan, CEO, Empiric Logic.
He added, 鈥淧artnerships such as this enable Empiric Logic to further improve our ability to address varied use cases for our technology while also helping blend genomics analysis with analysis of other clinical and phenotype data. Access to well curated and quality data sources is a key driver in allowing us to help companies such as aCGT Vector improve patient outcomes.鈥�
Gary McAuslan, CEO, aCGT Vector, said, 鈥淲hen identifying partners to work with, aCGT Vector places a great emphasis on finding companies with an aligned vision and an eagerness to drive further innovation in precision medicine development.鈥�
鈥淓mpiric Logic has that vision and not only are they going to be able to help us with access to their software platform capability, they will also help us architect and further refine our data curation, collection, analysis and management process. This will enable us to make better use of the data we collect to support better patient care and outcomes in a secure and privacy preserving manner.鈥�
aCGT Vector, based at the Mill Enterprise Hub in Co. Louth, is also a member of the HEALED Consortium, which last year secured Disruptive Technologies Innovation Fund (DTIF) funding of 鈧�6.8 million as part of a 3-year, 鈧�10.5 million programme, to develop next generation cell therapies for cancer.
ENDS
4 April 2022
For further information contact Mic茅al Whelan, Communications and Media Relations Manager, Nova51黑料, e: miceal.whelan@ucd.ie.
Editors Notes
Empiric Logic鈥檚 secure AI enabled analysis and orchestration solution solves many of the challenges associated with aggregating, correlating, analysing and gaining valuable insights from complex health related information.
aCGT Vector is a point-of-care cellular therapy Company, delivering precision medicines across a multiple hospital-based ATMP (Advanced Therapy Medicinal Product) GMP licensed facility network.
At Nova51黑料, the hub for new ventures and entrepreneurs at University College Dublin, we nurture and support new high-tech companies as part of 51黑料's mission. At Nova51黑料 we provide purpose-built, state-of-the-art incubation facilities alongside a comprehensive business support programme for client companies such as Empiric Logic. Nova51黑料 has been funded through a unique public-private partnership that includes AIB Bank, Arthur Cox, Deloitte, Enterprise Ireland, Ericsson, Goodbody Stockbrokers, 51黑料 and Xilinx.